이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. (PRXS-SINGLE)

2026년 11월 10일 업데이트: Medical University of Silesia

Changes in Inflammatory Lesion Count, Tolerability, and Clinical and Instrumental Skin Parameters Following Five PRX S Sessions Combined With Standardized Home Care in Adults With Mild-to-Moderate Facial Acne: A Prospective, Single-Arm, Open-Label Clinical Study.

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

연구 유형

중재적

등록 (추정된)

30

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Anna Deda, PhD
  • 전화번호: +48 500 233 457
  • 이메일: adeda@sum.edu.pl

연구 장소

      • Mysłowice, 폴란드, 41-400
        • AJ Med
        • 연락하다:
      • Sosnowiec, 폴란드, 41-208
        • Department of Practical Cosmetology and Skin Diagnostics
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults aged 18-60 years.
  • Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
  • Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
  • Provision of written informed consent to participate in the study and undergo study-related assessments and documentation.
  • No contraindications to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
  • Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
  • No urgent need for alternative acne treatment that is not provided within the study protocol.

Exclusion Criteria:

  • Investigator's Global Assessment (IGA) grade 0, 1, or 4.
  • Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
  • Pregnancy or breastfeeding.
  • Known hypersensitivity to any component of the study products.
  • Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
  • Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
  • Skin malignancy or suspicious lesions in the treatment area.
  • Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
  • Use of topical retinoids within 30 days before baseline (T0).
  • Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
  • Completion of isotretinoin therapy less than 6 months before baseline (T0).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PRX S Treatment Combined With Standardized Home Care

Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group.

PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions.

All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70
기간: Baseline (Day 0) and Day 70 (14 days after the fifth treatment)

The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions.

Baseline (Day 0) and Day 70 (14 days after the fifth treatment)

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42
기간: Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).

Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement.

Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up
기간: Baseline (Day 0) and T3 (two calendar months after Day 70).

Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions.

Baseline (Day 0) and T3 (two calendar months after Day 70).
Change From Baseline in Facial Comedone Count
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change in Investigator's Global Assessment of Acne Severity
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1
기간: Day 42, Day 70, and T3 (two calendar months after Day 70).

Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe).

Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage of Participants Achieving Investigator's Global Assessment Success
기간: Day 42, Day 70, and T3 (two calendar months after Day 70).

IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1.

Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Stratum Corneum Hydration Measured by Corneometry
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D
기간: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Anna Deda, PhD, Medical University of Silesia in Katowice, Poland

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2027년 3월 30일

연구 완료 (추정된)

2027년 5월 31일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • PRXS-SINGLE-2026-01

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.

IPD 공유 기간

De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.

IPD 공유 액세스 기준

De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .